If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
==== General paleoanthropology ==== Cerrito, Burkart & van Schaik (2026) review the techniques used to extract information on life history from hominin fossils. Towle (2026) reviews longstanding issues in the systematics of hominins, including non-monophyly of at least the genus Australopithecus and mosaic trait distribution among hominin taxa, and proposes to subsume the genera Paranthropus and Australopithecus within the genus Homo. Begun (2026) reviews the fossil record of African apes and humans, and argues that the lack of hominin fossils from Africa from the interval between 13.5 and 6–7 million years ago might not simply be the result of incompleteness of the fossil record, and is potentially consistent with the origin of hominins in Eurasia and their dispersal into Africa after 7 million years ago. Gardner et al. (2026) study changes of body size throughout the evolutionary history of hominins, and interpret their finding as consistent with marked body mass increase in members of the genus Homo other than Homo habilis and Homo rudolfensis. A study on the morphological diversity of the femur and the humerus in extant hominids is published by Aramendi (2026), who interprets her findings as indicative of variable utility of different long bones for taxonomic indentification of hominin fossils, and as indicating that some of the variability observed in isolated or fragmentary hominin fossils might not be caused by presence of more than one taxon in the studied fossil material.
In the 1930s, the French enologist Jean Ribéreau-Gayon published papers stating the benefits of this bacterial transformation in wine. During the 1950s, advances in enzymatic analysis allowed enologists to better understand the chemical processes behind malolactic fermentation. Émile Peynaud furthered enology understanding of the process and soon cultured stock of beneficial lactic acid bacteria was available for winemakers to use.
=== Interaction with cellular proteins === Localization of CK1δ to certain subcellular compartments can furthermore be initiated by its interaction with cellular proteins. In order to mediate interaction with CK1δ appropriate docking motifs need to be present in the respective proteins. Docking motif Phe-X-X-X-Phe has been identified in NFAT, β-catenin, PER, and proteins of the FAM83 family. As an example, nuclear CK1δ can be localized to nuclear speckles by its interaction with FAM83H. Another interaction motif is represented by the sequence Ser-Gln-Ile-Pro, which is present in microtubule plus-end-binding protein 1 (EB1). Numerous interaction partners for CK1δ have been described within recent years, forming strong interactions with CK1δ and therefore being more than simple substrate proteins. As mentioned above, interactions with CK1δ have been shown for AKAP450 and DDX3X. By initially performing yeast two-hybrid screens, interaction could also be confirmed for the Ran-binding protein in the microtubule-organizing center (RanBPM), microtubule-associated protein 1A, and snapin, a protein associated with neurotransmitter release in neuronal cells. Interactions with CK1δ have also been detected for the development-associated factors LEF-1 (lymphocyte enhancer factor-1) and the proneural basic helix-loop-helix (bHLH) transcription factor Atoh1. Finally, interaction of CK1δ with PER and CRY circadian clock proteins have been demonstrated, facilitating nuclear translocation of PERs and CRYs.
Sources: en.wikipedia.org
Many kinds of isomerism exist in coordination complexes. Just as in organic chemistry, isomers are of two types: diastereomers (also called diastereoisomers) and enantiomers. Enantiomers are non-superimposable mirror images. Diastereomers are all other types of isomers.
=== Quantitative description === Reversible inhibition can be described quantitatively in terms of the inhibitor's binding to the enzyme and to the enzyme-substrate complex, and its effects on the kinetic constants of the enzyme. In the classic Michaelis-Menten scheme (shown in the "inhibition mechanism schematic" diagram), an enzyme (E) binds to its substrate (S) to form the enzyme–substrate complex ES. Upon catalysis, this complex breaks down to release product P and free enzyme. The inhibitor (I) can bind to either E or ES with the dissociation constants Ki or Ki', respectively.
== Publications == The ICHR publishes online as well as on print media. It publishes two journals: the Indian Historical Review (bi-annually) and Itihas (in Hindi). It also provides publication subsidies to seminars, books, congress proceedings, and journals. The editing and publication has been outsourced to certain publishing houses.
Wool Bradford, Halifax and Huddersfield grew through the development of woollen mills. Leeds' traditional industry was the manufacturing of cloth while heavier engineering industries facilitated growth in South Leeds. The Heavy Woollen District covered towns such as Dewsbury, Batley, Morley, Ossett, Cleckheaton and Heckmondwike. The woollen and cloth industries declined throughout the twentieth century.
Sources: en.wikipedia.org
=== Membrane spanning === α-Helices are also the most common protein structure element that crosses biological membranes (transmembrane protein), presumably because the helical structure can satisfy all backbone hydrogen-bonds internally, leaving no polar groups exposed to the membrane if the sidechains are hydrophobic. Proteins are sometimes anchored by a single membrane-spanning helix, sometimes by a pair, and sometimes by a helix bundle, most classically consisting of seven helices arranged up-and-down in a ring such as for rhodopsins (see image at right) and other G protein–coupled receptors (GPCRs). The structural stability between pairs of α-Helical transmembrane domains rely on conserved membrane interhelical packing motifs, for example, the Glycine-xxx-Glycine (or small-xxx-small) motif.
=== Reproduction and development === Sows usually produce their first litter at the age of 3 to 5 years, with those living in more developed areas tending to get pregnant at younger ages. The breeding period usually occurs in the June–July period, though it can extend to August in the species' northern range. The breeding period lasts for two to three months. Both sexes are promiscuous. Males try to mate with several females, but large, dominant ones may violently claim a female if another mature male comes near. Copulation can last 20–30 minutes. Sows tend to be short-tempered with their mates after copulating. The fertilized eggs undergo delayed development and do not implant in the female's womb until November. The gestation period lasts 235 days, and litters are usually born in late January to early February. Litter size is between one and six cubs, typically two or three. At birth, cubs weigh 280–450 g (0.62–0.99 lb) and measure 20.5 cm (8.1 in) in length. They are born with fine, gray, down-like hair and their hind quarters are underdeveloped. They typically open their eyes after 28–40 days and begin walking after 5 weeks. Cubs are dependent on their mother's milk for 30 weeks and will reach independence at 16–18 months. At 6 weeks, they attain 900 g (2.0 lb), by 8 weeks they reach 2.5 kg (5.5 lb) and by 6 months they weigh 18 to 27 kg (40 to 60 lb). They reach sexual maturity at 3 years and attain their full growth at 5 years.
The BOP was aware that the use of pentobarbital as their "new drug choice" would be challenged in the courts because some lawyers had said that "pentobarbital would flood prisoners' lungs with froth and foam, inflicting pain and terror akin to a death by drowning." BOP claimed that these concerns were unjustified and that their two expert witnesses asserted that the use of pentobarbital was "humane". On 25 July 2019, US Attorney General William Barr directed the federal government to resume capital punishment after 16 years, despite shortages of the compound caused by European Union restrictions and a lack of U.S. manufacturers. The federal protocol provides for intravenous administration of two syringes each containing 2.5 grams of pentobarbital sodium followed by a saline flush.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.